Sign In |  User Pages

Home | About Us | Distributors | Links | Partners | Downloads | Contact Us | On-line Catalog | Shopping Cart

About HemoGenix®

  • About Us

  • Scientific Advisory Board

  •  Join our Team

About Us

HemoGenix® is a privately held company located in Colorado Springs, Colorado. HemoGenix® was founded in March 2000 by Ivan N. Rich, PhD, an internationally recognized researcher in the field of developmental, experimental and applied clinical hematology. HemoGenix® was initially formed as a Contract Research Service Laboratory for the biopharmaceutical industry to test new drug candidates for their effect on stem and other primitive cells of the blood-forming system. HemoGenix® was the first company to provide true, high throughput screening and testing in vitro assays that provided a high degree of predictive value that can be directly extrapolated to the human situation. Virtually all the patented and proprietary assays developed by HemoGenix® have also been further developed into assay kits for in-house use that are produced, manufactured and sold around the world from the Colorado Springs facility. 

 

A Short Chronology of HemoGenix® Products

  • Development of the first HALO® assay started in January 2002 with help from a SBIR grants from the National Cancer Insitute (NCI).
  • HALO® assay for hemotoxicity testing launched at the Society of Toxicology meeting in San Francisco, CA in March 2002.
  • The first HALO® Research Kit Platform was launched at the American Society of Hematology Meeting in December 2003.
  • At the Society of Toxicology meeting in 2004, the first HALO® Hemotoxicity Kits and the OxyFLOW™ Platform were introduced.
  • In December 2004, at the American Society of Hematology, the first in a series of assays for the cellular therapy field was introduced. The first assay was HALO®-96 SPC-QC (Stem and Progenitor Cell - Quality Control).  In addition, the first LUMENESC™ Kit Platform to detect Mesenchymal Stem Cells (MSC) were also introduced.
  • In March 2005, the HALO® Predictive Hemotoxicity Platform was unveiled at the Society of Toxicology.
  • In December 2005, HemoGenix®, launched the LumiSTEM™ Platform.
  • Shortly thereafter, the ComparaTOX™ Platform was launched introducing the concept of "In Vitro Cross-Platform Comparative Toxicity"
  • In 2006, Suspension Expansion Culture (SEC) Technology was introduced for all HALO® assays. It also heralded the introduction of the first and only 384-well plate high throughput platform for hemotoxicity screening (HALO®-384 HT). 
  • In December 2007, the first stem cell potency assay (HALO®-96 PQR) for umbilical cord blood was made commercially available.
  • Between 2009 and 2010, several new in vitro assays were introduced by HemoGenix®. These included HALO®-96 PMT, LumiCLONE™, LumiSTEM™-iPS and LumiCYTE™ for hepatotoxicity.
  • In addition, similar assays to HALO®-96 SPC-QC and HALO®-96 PQR for blood stem cell quality control and potency testing were introduced for the mesenchymal stem cell system, namely LUMENESC™-96 HuQC and LUMENESC™-96 PQR.
  • The latest assay introduced to the hematopoietic cellular therapeutic field from the HemoGenix® Laboratories has been STEMpredict™. This is the fastest and most reliable blood stem cell growth, functionality and viability assay commercially available.
  • In January 2012, HemoGenix® launched the largest number of new assays in its history. These included fluorescence and absorbance equivalent assays to its HALO® and LUMENESC™ platforms and a new assay platform for immune cells that incorporates all three proliferation readouts, bioluminecence, fluorescence and absorbance. 

 

In addition to performing contract service and producing assay kits for stem cell, basic and veterinary research, the biopharmaceutical industry and in vitro environmental testing and assays for cellular therapy, HemoGenix® is the exclusive distributor in the Americas and Asia for Pecon GmbH, Germany that produces The POC Tissue Culture Chamber Systems and numerous accessories for microscopes.

 

About the Founder & CEO

 

Ivan N. Rich, PhD is Founder, Chairman and
CEO of HemoGenix®, Inc and adjunct Professor in the Department of Biology at the University of Colorado at Colorado Springs. Dr. Rich is also the inventor of all of the patented and proprietary assays used by HemoGenix® today.

Dr. Rich obtained his BSc in biochemistry at the University of Sussex in Brighton/Falmer, England in 1973. He completed his PhD in 1978 at the University of Ulm in Ulm, Germany and completed a second thesis in Experimental Hematology in 1995. His postdoctoral research was performed at the University of Chicago between 1981 and 1983 with Dr. Eugene Goldwasser who, together with his associates, was responsible for obtaining the first partial amino acid sequence of purified erythropoietin (EPO) that eventually led to the production of the first human recombinant EPO used around the world to alleviate the symptoms of chronic anemia. Dr. Rich moved to the United States in 1996.

Dr. Rich has authored 49 peer-reviewed publications, 33 reviews and book chapters and has attended and presented at numerous international conferences. He also organized and edited conference proceedings for a NATO Advanced Research Workshop. Together with Terrance R.J. Lappin, PhD, Professor of Hematology at Queen's University in Belfast, Northern Ireland, he also organized and edited the proceedings of a New York Academy of Science Workshop on Erythropoietin.

Ivan Rich belongs to several societies including
the Colorado Biotechnology Association, the American Society of Hematology (ASH), the International Society of Experimental Hematology (ISEH), the British Society of Haematology, International Society for Stem Cell Research (ISSCR), the International Society of Cellular Therapy (ISCT), AABB (American Association of Blood Banks), the Society of Toxicology (SOT) and the Society Laboratory Automation and Screening (SLAS). He has also been a reviewer for many scientific journals and grant agencies around the world.

 

 

Peer-Reviewed Articles

  1. Rich IN & Kubanek B. Erythroid colony formation (CFUe) in fetal liver and adult bone marrow and spleen from the mouse. Blut (1976), 33:171-180.
  2. Opitz U, Seidel H-J & Rich IN. Erythroid stem cells in Rauscher virus infected mice. Blut. (1977), 35:35-44.
  3. Hansi W, Rich IN, Heit W, Kubanek B & Heimpel H. Erythroid colony-forming cells in aplastic anemia. Brit. J. Haematol. (1977), 37:483-488.
  4. Rich IN & Kubanek B. The ontogeny of erythropoiesis in the mouse detected by the erythroid colony-forming technique. I.Hepatic and maternal erythropoiesis. J. Embryol. exp. Morph. (1979), 50:57-74.
  5. Rich IN & Kubanek B. The ontogeny of erythropoiesis in the mouse detecetd by the erythroid colony-forming technique. II. Transition in erythropoietin sensitivity during development. J. Embryol. exp. Morph. (1980), 58:143-155.
  6. Rich IN, Heit W & Kubanek B. The effects of actinomycin D on erythropoiesis. I. Short-term effects. Blut. (1980), 41:29-40.
  7. Rich IN & Kubanek B. An erythropoietic stimulating factor similar to erythropoietin released my macrophages after treatment with silica. Blut. (1980), 40:297-303.
  8. Pentz S, Vergani G, Amthor A, Horler H & Rich IN. A method for electron microscopic preparation of cultured cells (monolayer) in a new test chamber (TCSC-1). Microscopica Acta. (1981), 84:117-120.
  9. Rich IN, Anselstetter V, Heit W, Zanjani E & Kubanek B. Release of erythropoietin from macrophages by treatment with silica. J. Supramol. Struct. & Cell. Biochem. (1981), 15:169-176. Also published in: UCN-UCLA Symposia Proceedings of Control of Cellular Division and Development. Part A. A.L. Liss, New York. (1981).
  10. Rich IN, Sawatzki G & Kubanek B. Specific enhancement of mouse CFU-E by mouse transferrin. Brit. J. Haematol. (1981), 49:567-573.
  11. Rich IN & Kubanek B. Release of erythropoietin from macrophages mediated by phagocytosis of crystalline silica. J. Reticuloendo. Soc. (1982), 31:17-30.
  12. Rich IN, Heit W & Kubanek B. Extrarenal erythropoitein production by macrophages. Blood. (1982), 60:1007-1018.
  13. Rich IN & Kubanek B. The effect of reduced oxygen tension on colony formation of erythropoietic cells in vitro. Brit. J. Haematol. (1982), 52:579-588.
  14. Lappin TRJ, I.Rich & Goldwasser E. The effect of erythropoietin and other factors on DNA synthesis by mouse spleen cells. Exp. Hematol. (1983), 11:661-666.
  15. Rich IN. Hemopoietic regulation in vitro: In vivo significance of functionally similar multiactive potentiating factors. Collection des Annales de l'Institut Pasteur, Annales D'Immunologie. (1984), 135C:280-288.
  16. Rich IN. A role for the macrophage in normal hemopoiesis: I. Functional capacity of bone arrow macrophages to release hemopoietic growth factors. Exptl. Hemat. (1986), 8:738-745.
  17. Rich IN. A role for the macrophage in normal hemopoiesis: II. Effect of varying oxygen tensions on the release of hemopoietic growth factors from bone marrow-derived macrophages in vitro. Exptl. Hemat. (1986), 8:746-751.
  18. Rich IN, Vogt Ch, Pentz S. Erythropoietin gene expression in vitro and in vivo detected by in situ hybridization. Blood Cells (1988) 14:505-520.
  19. Rich IN. Haemopoietic regulation and the role of the macrophage in erythropoietic gene expression. Adv Exp Med Biol (1988) 241:55-66.
  20. Vogt Ch, Pentz S, Rich IN. A role for the macrophage in normal hemopoiesis: III. In vivo and in vitro erythropoietin gene expression in macrophages detected by in situ hybridization. Exp Hemat (1989) 17:391-397.
  21. Sawatzki G, Rich IN. Lactoferrin stimulates colony stimulating factor production in vitro and in vivo. Blood Cells (1989) 15:371-385.
  22. Rich IN, Sawatzki G. Lactoferrin, the signal for colony stimulating factor production? Negative-feedback regulation versus supply-and-demand regulation of myelopoiesis. Blood Cells (1989) 15:400-406.
  23. Vogt Ch, Noé G, Rich IN. The role of the blood island during normal and 5-fluorouracil-perturbated hemopoiesis. Blood Cells. (1991), 17:105-125.
  24. Rich IN. The effect of 5-Fluorouracil on erythropoiesis. Blood (1991), 77:1164-1170.
  25. Rich IN. The site of erythropoietin production: Localization of erythropoietin mRNA by radioactive in situ hybridization. Blood (1991), 78:2469.
  26. Rich IN. The developmental biology of murine hemopoiesis: Effect of growth factors on colony formation by embryonic cells. Exp Hemat (1992), 20:368.
  27. Noé G, Riedel W, Kubanek B, Rich IN. A sensitive sandwich ELISA for measuring erythropoietin in human serum. Brit J Haematol (1992), 80:285.
  28. Gebicke-Haerter PJ, Appel K, Taylor GD, Schobert A, Rich IN, Northoff H, Berger M. Rat microglial interleukin-3. J Neuroimmunol (1994) 50:203
  29. Rich IN, Kubanek B. The autonomous release of erythropoietic inhibition during long-term in vivo administration of actinomycin D. Exp. Hematol. (1994) 22:347.
  30. Schrezenmeier H, Noé G, Raghavachar A, Rich IN, Heimpel H, Kubanek B. Serum erythropoietin and serum transferrin receptor levels in aplastic anaemia. Brit. J. Haemat. (1994) 88:286-294.
  31. Rich IN. Hemopoietic-initiating cells. J Perinat Med 23:31-38 (1995).
  32. Rich IN. Primordial germ cells are capable of producing cells of the hemopoietic system in vitro. Blood 86:463 (1995).
  33. Noè G, Augustin J, Hausdorf S, Rich IN, Kubanek B. Serum erythropoietin and transferrin receptor levels in patients with rheumatoid arthritis. Clin Exp Rheumatol 13:445-451 (1995).
  34. Gunga H-C, Kirsch KK, Rich IN, Rocker L. Erythropoietin after long-term spaceflight (30 d). Aviation, Space and Environ Med 66:913 (1995).
  35. Zimmermann F and Rich. The sensitivity of in vitro erythropoietic progenitor cells to different erythropoietin reagents during development and the role of cell death in culture. Exp Hemat 24:330-339 (1996)
  36. Gunga H-C, Roecker L, Behn C, Hildebrandt W, Koralewski E, Rich I, Schobersberger W, Kirsch K. Shift working at high altitude in the Chilean Andes (>3,600 m) and is influence on erythropoietin and the low pressure system. J Appl Physiol (1996)
  37. Gunga H-C, Kirsch K, Baartz F, Maillet A, Gharib C, Nalishiti W, Rich I, Roecker L. Erythropoietin under real and simulated micro-g conditions in man. J Appl Physiol (1996).
  38. Zimmermann F and Rich IN. Mammalian homeobox B6 (HOX B6) expression can be correlated with erythropoietin production sites and erythropoiesis during development, but not with hemopoietic or non-hemopoietic stem cell populations. Blood 89:2723-2735 (1997).
  39. Rich IN. Standardization of the CFU-GM assay using hematopoietic growth factors. J. Hematotherapy:6:191-192 (1997).
  40. Rich IN, Brackmann I, Dewey MJ, Worthington-White D. Activation of the sodium/hydrogen exchanger via the fibronectin-integrin pathway results in hematopoiesis stimulation. J Cell Physiol. 177:109-122 (1998).
  41. Noé G, Riedel W, Kubanek B, Rich IN. An ELISA specific for murine erythropoietin. Brit J Hematol 104:838-840 (1999).
  42. Garden OA, Musk P, Worthington-White DA, Dewey M, Rich IN. Silent polymorphisms within the coding region of human sodium/hydrogen exchanger isoform-1 cDNA in peripheral blood mononuclear cells of leukemia patients: A comparison with healthy controls. Cancer Genet and Cytogenet 120:37-43 (2000).
  43. Rich IN, Worthington-White D, Garden OA, Musk P. Apoptosis of leukemic cells correlates with reduction in intracellular pH after targeted inhibition of the Na+/H+ exchanger. Blood 95:1427-1434 (2000).
  44. Rich IN. In vitro hemotoxicity testing in drug development. A review of past, present and future applications. Current Opinion in Drug Discovery and Development. 6:100-109 (2003).
  45. Lis CG, Grutsch JF, Wood P, You M, Rich IN, Hrushesky WJM. Circadian timing in cancer treatment: The biological foundation for an integrative approach. Integrative Cancer Therapies. 2:105-111 (2003).
  46. Rich IN and Hall KM. Validation and development of a predictive paradigm for hemotoxicology using a multifunctional bioluminescence colony-forming proliferation assay. Tox Sci 87:427-441 (2005).
  47. Rich IN. High-throughput in vitro hemotoxicity testing and in vitro cross-platform comparative toxicity. Expert Opin Drug Metab Toxicol. 3:295-307 (2007).
  48. Reems JA, Hall KM, Gebru LH, Taber G, Rich IN. Development of a novel assay to evaluate the functional potential of umbilical cord blood progenitors. Transfusion. 48:620-628 (2008).
  49. Hall KM, Harper H, Rich IN. Hematopoietic Stem Cell Potency for Cellular Therapeutic Transplantation.
    (2012). Advances in Hematopoietic Stem Cell Research, Rosana Pelayo (Ed.), ISBN: 978-953-307-930-1, InTech.

 

Reviews and Book-Chapters

  1. Kubanek B, Heit W & Rich IN. Fetal erythropoiesis. In: Fetal Liver Transplantation. Current Concepts and Future Trends. Eds. G. Lucarelli, T.M. Fliedner & R.P. Gale. Excerpta Medica/North Holland (1980) pp 70-78.
  2. Rich IN, Anselstetter V, Heit W & Kubanek B. The role of the macrophage in extrarenal erythropoietin production and ontogeny in mouse and man. In: Fetal Liver Transplantation. Current Concepts and Future Trends. Eds. G. Lucarelli, T.M. Fliedner & R.P. Gale. Excerpta Medica/North Holland. (1980) pp 95-107.
  3. Kubanek B & Rich IN. Fetal erythropoiesis. In: Adv. Physiol. Sci. Vol 6. Genetics, Structure and Function. Eds. S.R. Holland, G. Gardos & B. Sarkodi. Pergamon Press. (1981) pp 147-151.
  4. Heit W, Rich IN & Kubanek B. Macrophage-dependent production of erythropoietin and colony-stimulating factor. In: Hematology and Blood Transfusion Vol. 27. Disorders of the Monocyte Macrophage System. Eds. F. Schmalzl, D. Huhn, H.E. Schaefer. Springer-Verlag Heidelberg. (1981) pp.73-78.
  5. Goldwasser E, Ihle JN, Prystowsky MB, Rich IN & van Zant G. The effect of Interleukin 3 on hemopoietic precursor cells. In: Normal Neoplastic Hemopoiesis. Symposium on Molecular and Cell Biology. Eds. D. Golde, P. Marks & C.F. Fox. A.L. Liss, New York. (1983) pp 301-309.
  6. Rich IN. The effect of silica on hemopoiesis: Evidence for the macrophage acting as a regulator cell. Immunology and Hematology Research. Monograph (1984), No. 3. pp.175-178.
  7. Rich IN. Macrophage-derived hemopoietic humoral factors: regulatory role of the macrophage in hemopoiesis. In: New Trends in Experimental Hematology. Oncogenes, Stem Cells, Bone Marrow Transplantation. Eds. C. Peschle & C. Rizzoli. Serono Symposia Review (1984),No. 7. pp.27-33. .
  8. Rich IN. The central role of the macrophage in hemopoietic microenvironmental regulation. In: Cronkite EP, Dainiak N, McCaffrey RP, Palek J, Quesenberry PJ (Eds), Hemopoietic Stem Cell Physiology. Alan R. Liss. New York. (1985) pp 283-300.
  9. Rich IN. The macrophage as a producer of erythropoietin: Response to physiological oxygen tensions and detection of gene expression using in situ hybridization. In: Rich IN (Ed) Molecular and Cellular Aspects of Erythropoietin and Erythropoiesis, Springe-Verlag, Heidelberg (1987) pp. 291-310.
  10. Frickhofen N., Raghavachar A., Rich I., Heit W. & Heimpel H. Inhibition of hematopoietic progenitor cells by a variant of the L1210 leukemia cell line. In: Proceedings of the 1st International Symposium on Inhibitory Factors in the Regulation of Hematopoiesis. Najman A., Guigon M., Gorin N-C., Mary J-Y. (Eds). John Libby Eurotext, London, Paris (1987) pp 213-216.
  11. Rich IN & Sawatzki G. The role of lactoferrin in regulating colony stimulating factor production. In: Proceedings of the 1st International Symposium on Inhibitory Factors in the Regulation of Hematopoiesis. (1987). Najman A., Guigon M., Gorin N-C., Mary J-Y. (Eds). John Libby Eurotext, London, Paris (1987) pp 63-67.
  12. Rich IN. Oxygen Tension and erythropoietin production: The role of the macrophage in regulating erythropoiesis. In: Oxygen Sensing in Tissues, H. Acker (ed) Springer-Verlag, (1988) pp 113-120.
  13. Rich IN, Vogt Ch. Pentz S. Erythropoietin gene expression in macrophages detected by in situ hybridization. Behring Institute Mitteilung (1988) pp. 202-206.
  14. Rich IN. The macrophage as a production site for hematopoietic regulator molecules: Normal and pathophysiological signals. Anticancer Research. (1988) 8:1015-1040.
  15. Rich IN. Erythropoietin production under steady-state conditions: Detection and localization using in situ hybridization. In: Erythropoietin, Jelkmann W, Gross AJ (Eds). Springer Verlag (1989), pp 19-25.
  16. Rich IN. Oxygen sensing mechanisms in the macrophage and erythropoietin production. In: Arterial Chemoreception, Eyzaguirre C, Fidone SJ, Fitzgerald RS, Lahiri S, McDonald D. Springer Verlag. (1990) pp. 113-120.
  17. Vogt Ch, Noé G, Rich IN. Normal steady-state hemopoiesis. Assay of erythropoietin by ELISA, localization of erythropoietin in the kidney and expression of hemopoietic regulator molecules in the bone marrow. In: Molecular Biology of Hemopoiesis. Sachs L, Abraham N, Weidermann C, Konwalinka C (Eds). Intercept Ltd. Andover, U.K. (1990) pp 401-412.
  18. Rich IN. Molecular and cellular aspects of erythropoietin and erythropoiesis --- From 1986 to 1990. In: Recent Advances in Cell to Cell Signals in Plants and Animals. Neuhoff V, Friend J (Ed). Springer Verlag, Heidelberg. NATO ASI Series H. (1991) Vol 51:118-132.
  19. Rich IN. Erythropoietin Production -- A Personal View. (Invited review) Exp Hemat (1991), 19:985-990.
  20. Rich IN & Noé G. The developmental biology of erythropoiesis and erythropoiesis. Is erythropoietin a true hormone or a paracrine factor? In: 2nd International Meeting of Erythropoietin Pathophysiology in Lübeck. (1992) pp.79-87.
  21. Noë G, Rich IN, Kubanek B. A sensitive ELISA for erythropoietin and its application in various diseases. In: 2nd International Meeting of Erythropoietin Pathophysiology in Lübeck. (1992) pp.109-116.
  22. Schrezenmeier H, Noë G, Rich IN, Raghavachar A. Serum erythropoietin levels in aplastic anemia determined by ELISA. In: 2nd International Meeting of Erythropoietin Pathophysiology in Lübeck. (1992) pp. 225-231.
  23. Ploemacher RE, Rich IN. Congress Letter. Summary of the European Stem Cell Club. Leukemia (1992) 6:1081-1082.
  24. Noé G, Schrezenmeier H, Rich IN, Kubanek B. Circulating erythropoietin levels in pathophysiological conditions. In: Molecular, Cellular and Developmental Biology of Erythropoietin and Erythropoiesis. IN Rich and TRJ Lappin (Eds). Annals of the New York Academy of Sciences (1994) 718:94.
  25. Rich IN, Riedel W, Zimmermann F, Vogt Ch, Noé G. The initiation of the hemopoietic system. The response of embryonic cells to growth factors and expression of erythropoietin and erythroid-relevant genes during murine development. In: Molecular, Cellular and Developmental Biology of Erythropoietin and Erythropoiesis. IN Rich and TRJ Lappin (Eds). Annals of the New York Academy of Sciences (1994) 718:140.
  26. Kubanek B, Rich IN, Noé G. Erythropoietin. Infusionstherapie und Transfusionsmedizin. (1994) 21:46-50.
  27. Rich IN. Hemopoietic - Initiating Cells. J. Perinatal Medicine 23 (1/2): 31-38 (1995)
  28. Lappin TRJ and Rich IN. Erythropoietin - The first 90 years. Clin. Lab Hematol 18:137-145(1996)
  29. Van Zant G, de Haan G, Rich IN. Alternative to stem cell renew from a developmental viewpoint. Exp. Hemat (Review) 25:187-192 (1997).
  30. Rich IN. Homeobox genes and hematopoiesis. J Hematotherapy 7:515-520 (1998).
  31. Rich IN. Monocytes and Macrophages. In: Human Cell Culture, Volume 4, Primary Hematopoietic Cells, MR Koller and BO Palsson (Eds). Kluwer Academic Press pp125-146 (1999).
  32. Rich IN. Predictive stem cell hemotoxicity testing. Assay Tutorial. Genetic Engineering News. 24/7:32-33 (2004).
  33. Hall KM, Harper H, Rich IN. (2012) Hematopoietic stem cell potency for cellular therapeutic transplantation. In: Hematopoietic Stem Cells, Ed. Rosana P. Camacho. Published by: InTech Open Access Publisher. ISBN 978-953-307-746-8.

 

Books and Monographs


  1. Rich IN, Editor: Molecular and Cellular Aspects of Erythropoietin and Erythropoiesis. NATO Advanced Science Institute, Springer Verlag. (1987).
  2. Rich IN, Lappin TRN (Editors). Molecular, Cellular and Developmental Biology of Erythropoietin and Erythropoiesis. New York Academy of Science. (1994) Vol. 718.

 

Scientific Advisory Board

 

Jo-Anna Reems, Ph.D., MT (ASCP), SBB

HemoGenix® welcomes Dr. Jo-Anna Reems as a specialist in Cellular Therapy to the Scientific Advisory Board.

 

Dr. Reems currently holds three positions as Associate Professor at the University of Washington, Seattle, Investigator in the Clinical Research Division at the Fred Hutchinson Cancer Center in Seattle, WA and as Visiting Associate Professor at Colorado State University in Pueblo, CO. From 2007 to 2011, Dr. Reems was Scientific Director of Cellular Therapy at Puget Sound Blood Center in Seattle, WA. She received her Bachelor of Science degree in Medical Technology at the University of Colorado in Boulder, CO and went on to get her PhD in Biochemistry at the University of Colorado Health Sciences Center in Denver, CO in 1992. Prior to starting her postdoctoral training at the Fred Hutchinson Cancer Center in Seattle, WA in the field of hematopoietic regulators, she became a Specialist in Blood Banking at the American Red Cross in Norfolk, VA. In 1996, Dr. Reems took up the position of Scientific Director of Research at Blood Systems, Tempe, AZ and Adjunct Professor at Arizona State University in Tempe, AZ.

 

Dr. Reems is member of several societies including the International Society of Cellular Therapy (ISCT), American Association of Blood Banks (AABB), American Society of Hematology and the International Society of Hematology. She received the National Blood Foundation Scholar Award in 2000 from AABB and has been principal and co-investigator on many grants from the National Institutes of Health. She was also Project Director of one of the first public cord blood banks to receive funding from the Department of Health and Human Services for the National Cord Blood Inventory (NCBI) of the C.W. Bill Young Cell Transplantation Program in 2006. She has made significant contributions at a regional, national and international level to the field of cord blood banking and is a Scientific Member of the Biomedical Excellence for Safer Transfusion (“BEST”).

 

Dr. Reems has been an invited speaker at many scientific meetings and is also a reviewer for several journals including Transfusion, Stem Cells and Cytotherapy. Dr. Reems has published more than 50 articles in peer-reviewed journals as well as many book chapters and reviews.

 

 

Andrew Olaharski, Ph.D., DABT

Andrew Olaharski brings toxicological experience and knowledge to the HemoGenix® Scientific Advisory Board.

 

Dr. Olaharski received his Ph.D in Environmental Toxicology from the University of California, Riverside in 2004 and was a postdoctoral researcher for several years in the Molecular Epidemiological and Toxicology Laboratory (METL) located at the University of California, Berkeley.

 

Dr. Olaharski began his career in the pharmaceutical industry at Roche, Palo Alto, where he worked as a discovery and investigative toxicologist. Over the next five years he was provided increasing roles and responsibilities, working at the Hoffmann-La Roche Basel, Switzerland and Nutley, NJ research and development sites, where he ultimately became a principal research scientist and head of the early safety representatives. He provided safety guidance to discovery project teams in the oncology, virology and inflammatory therapeutic areas, was instrumental in developing new techniques to better predict kinase-mediated genetic and bone marrow toxicities and directed the evaluation and implementation of novel in vitro assays. He is presently Associate Director in Non-Clinical Safety Evaluation at Elan Pharmaceuticals in South San Francisco, CA.

 

Andrew has authored or co-authored more than a dozen impactful articles, had his work highlighted on the cover of Toxicological Sciences, presented at national and international symposia and received numerous honors and awards, including the first prize for the Roche 3Rs Award for the development of a high throughput in vitro bone marrow assay. He is a member of the Society of Toxicology and is vice president elect for the Drug Discovery Toxicology Specialty Section of that society. He is a reviewer for many scientific journals, including Carcinogenesis, Environmental and Molecular Mutagenesis, Toxicology Letters and Toxicological Sciences He is a board certified toxicologist, having become a Diplomat of the American Board of Toxicology in 2008.

 

 

Independent Sale Representative

Hemogenix is currently seeking independent and qualified sales representatives to promote and initiate contract research servicess to biopharma and increase its assay kit sales to investigators at academic institutions and clinical and cord blood bank stem cell processing laboratories.

Applicants must have a minimum of a Bachelors degree, preferably in one of the biological sciences. The applicant must have experiance with in drug development and be able to communicate with academic professionals and laboratory technicians alike.

Interested applicants should send their complete resume to info@hemogenix.com. Please include territories covered and sales.

Hemogenix Inc.